XOMA Royalty Corporation Depositary Shares Rep Series B 8.375% Cumulative Preferred Stock
XOMAOXOMA Royalty Corporation Depositary Shares Rep Series B 8.375% Cumulative Preferred Stock (XOMAO) represents a preferred equity security issued by XOMA Royalty Corporation. It offers investors a fixed cumulative dividend rate of 8.375%, payable annually, and typically has priority over common stock in dividend payments and asset distribution. The shares are often structured as depositary receipts, allowing investors to hold fractional interests in the preferred stock.
Dividend History
| Pay Date | Amount | Ex-Date | Record Date |
|---|---|---|---|
| October 15, 2025 | $0.52 | 2025-10-03 | 2025-10-03 |
| July 15, 2025 | $0.52 | 2025-07-03 | 2025-07-03 |
| April 15, 2025 | $0.52 | 2025-04-03 | 2025-04-03 |
| January 15, 2025 | $0.52 | 2025-01-03 | 2025-01-03 |
| October 15, 2024 | $0.52 | 2024-10-03 | 2024-10-03 |
Dividends Summary
- XOMA Royalty Corporation Depositary Shares Rep Series B 8.375% Cumulative Preferred Stock has issued 18 dividend payments over the past 4 years
- The most recent dividend was paid 54 days ago, on October 15, 2025
- The highest dividend payed out to investors during this period was $0.56 per share
- The average dividend paid during this period was $0.53 per share.
Company News
Mural Oncology has completed a scheme of arrangement with XOMA Royalty, where XOMA will acquire the entire issued share capital of Mural. The transaction became effective on December 5, 2025, with share trading cancellation and shareholder consideration distribution expected soon.
Mural Oncology announced the final details of its acquisition by XRA 5 Corp., a subsidiary of XOMA Royalty, with a total cash consideration of $2.035 per share. The acquisition is expected to close in early December 2025, subject to Irish High Court sanction.
XOMA Corporation, a biotechnology company, announced that it will change its name to XOMA Royalty Corporation, effective July 10, 2024. The rebranding reflects the company's focus on pharmaceutical royalties.
XOMA Corporation operates as a biotechnology royalty aggregator, acquiring economic rights to milestones and royalties from approved or clinical-stage drugs.
